Tackling NTDs

Introduction of global public-private partnership initiatives

Participation in "WIPO Re:Search" to Develop Drugs and Vaccines for Tropical Diseases Since 2011, the World Intellectual Property Organization (WIPO) has sponsored the Global Initiative "WIPO Re:Search", a consortium to develop drugs and vaccines for the treatment of malaria, tuberculosis, NTDs and other infectious diseases. Eisai and Takeda, members of the JPMA have been participating.
Through WIPO Re:Search, both companies have been cooperating in compound screening for medicines at research institutions in various countries including Africa as well as in developing vaccines.
Participation in the London Declaration on Neglected Tropical Diseases In 2012, Eisai, together with 12 pharmaceutical companies worldwide, announced a joint statement that includes the Bill and Melinda Gates Foundation, the World Health Organization (WHO), the World Bank, the U.S. and British governments and governments from countries that are endemic for NTDs, built the largest global public-private partnership in global health. The partnership announced "London Declaration", to work together to eliminate NTDs 10 diseases by 2020.

Public-Private Partnerships Originating from Japan "Global Health Technology Fund (Global Health Innovative Technology Fund, GHIT Fund)"

In Japan, there is a growing movement to take the initiative in resolving these issues in developing countries through public-private cooperation. In 2013, the Japan-initiated Public-Private Partnership "Global Health Technology Fund (Global Health Innovative Technology Fund, GHIT Fund)" was established as a groundbreaking initiative for private sector companies to take the initiative and become involved as funding partners. The GHIT Fund was established as the world's first fund specializing in global health research and development through joint funding by government, business, and citizens in partnership across sectors. GHIT fund subsidizes Japan-overseas joint R & D projects for commercialization of drugs, vaccines, and diagnostic agents needed by the poorest people in developing countries to overcome the three major infectious diseases and NTDs.

GHIT Participating Companies

The following companies are participating in the GHIT Fund as partners (As of July 2020).

Full partners Astellas Pharma Inc., Chugai Pharmaceutical, Daiichi Sankyo Company, Limited, Eisai Co., Ltd., Shionogi & Co., Ltd., Takeda Pharmaceutical Company Limited.
Associate partners Fujifilm Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Sysmex K.K.
Affiliate partners GlaxoSmithKline K.K., Johnson & Johnson K.K., Kyowa Hakko Kirin Co., Ltd., Merck K.K., Mitsubishi Tanabe Pharma Corporation, Ono Pharmaceutical Co., Ltd. and Dainippon Sumitomo Pharma Co., Ltd.

The Japan Pharmaceutical Manufacturers Association aims to strengthen Japan's international contribution in the field of global health through the creation of new drugs for infectious diseases in developing countries by leveraging our strengths in new drug development based on advanced science and technology.